MEDLINE Journals

    Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.

    Authors
    Biganzoli L, Untch M, Skacel T, et al. 
    Source
    Semin Oncol 2004 Jun; 31(3 Suppl 8) :27-34.
    Abstract

    Neutropenia is a significant hematologic complication induced by cytotoxic chemotherapy. The clinical consequences of chemotherapy-induced neutropenia are often severe and can be potentially life-threatening. Patients who develop febrile neutropenia often need to be hospitalized, reducing their quality of life and increasing costs. Neutropenia can also compromise the ability to deliver chemotherapy at the full dose and on schedule. To help prevent the occurrence of neutropenia, patients with a high risk of developing chemotherapy-related infections may be given prophylactic colony-stimulating factors. Filgrastim is a recombinant human granulocyte colony-stimulating factor that has been widely used (in over 3 million patients) for over 12 years in the management of neutropenia. Pegfilgrastim is an approved, long-acting, next generation of granulocyte colony-stimulating factor that has similar clinical benefits to filgrastim but has novel pharmacokinetic properties. Pegfilgrastim shows at least comparable safety and efficacy to filgrastim, with the added benefit of simplified once-per-chemotherapy-cycle dosing. In addition, two randomized, controlled pivotal trials have shown that a single dose of pegfilgrastim given once per cycle led to a lower observed incidence of febrile neutropenia following myelosuppressive chemotherapy, compared with daily injections of filgrastim. Clinical trials are currently expanding the clinical experience with pegfilgrastim in a variety of solid tumors and hematologic malignancies. In addition to prevention of chemotherapy-induced neutropenia in 21- and 28-day regimens, future studies are examining the suitability of pegfilgrastim in dose-dense therapy and other cancer settings.

    Mesh
    Antineoplastic Agents
    Granulocyte Colony-Stimulating Factor
    Humans
    Neoplasms
    Neutropenia
    Recombinant Proteins
    Language

    eng

    Pub Type(s)
    Journal Article Research Support, Non-U.S. Gov't Review
    PubMed ID

    15181606

    Content Manager
    Related Content

    Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.

    Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.

    Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.

    Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.

    Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.

    Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.

    Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.

    Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.